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Cancer is thought to be largely caused by genetic mutations 
that alter nucleotide sequences of DNA, yet epigenetic fac-
tors are increasingly recognized to also play causative roles 
in cancer development. The idea of “epimutations” involves 
aberrations in chemical modification of the chromatin or 
DNA that do not change nucleotide sequence. While it is 
widely accepted that aberrations of DNA methylation con-
tribute to carcinogenesis, the functional importance of his-
tone modifications and other chromatin features in the de-
velopment of human cancer remains to be elucidated. Re-
cent efforts in large-scale sequencing of cancer genomes 
have revealed mutations in numerous chromatin regulatory 
genes, and thus demand further investigations on the epige-
netic mechanisms as driving forces in cancer development. 
SETD2 is a key histone modifying enzyme gene that is 
responsible for catalyzing trimethylation at the lysine 36 of 
histone H3 (H3K36me3). During transcriptional elongation 
in normal cells, H3K36me3 marks the zone on exons for 
accurate gene transcription and plays an important role in 
the regulation of alternative splicing. Recent studies also 
demonstrated that SETD2-mediated H3K36me3 is required 
for DNA mismatch repair (MMR). H3K36me3 facilitates 
MMR in cells by recruiting the MMR machinery to the 
chromatin during cell cycle. SETD2 was previously known 
for its frequent mutations in kidney cancer. A recent com-
prehensive study evaluating 12 major types of cancer by an 
international study also showed that SETD2 mutations are 
specific to certain types of solid tumors including kidney, 
lung and bladder cancers. In blood cancer, targeted se-
quencing of limited exons of SETD2 did not find mutations 
in an acute leukemia patient cohort consisting of childhood 
B-cell acute lymphoblastic leukemia (ALL) and adult acute 
myeloid leukemia (AML) [1]. One recent report identified 
SETD2 mutations in T-cell ALL, a specific type of acute 
leukemia originating from lymphoid lineage [2]. Despite the 
implications of SETD2 mutations in the pathogenesis of a 
number of human cancers, the functional role of SETD2 
mutations has not been clearly defined. 
Our new study [3] has demonstrated a definitive role of 
histone modifying gene SETD2 in a specific type of human 
blood cancer, leukemia. Disruption of the SETD2 function 
resulted in global loss of H3K36me3. In the presence of a 
major chromosomal translocation, SETD2 disruption great-
ly accelerated both initiation and progression of the disease. 
Acute leukemia characterized by chromosomal translo-
cations usually requires additional molecular disruptions to 
develop the full blown malignancy. Through whole genome 
sequencing, we looked for cooperating events and identified 
mutations in SETD2 in the genome of a monozygotic twin 
child who carried a major chromosomal translocation in-
volving the MLL gene and had developed acute leukemia. 
Intrigued by the SETD2 mutations in the genome of the 
leukemic twin sister, we carried out a subsequent screening 
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on more than 240 acute leukemia patients collected from 
several major medical centers in China and revealed a 6.2% 
frequency of SETD2 mutations in the entire leukemia cohort 
and 22% in patients with MLL translocations. More im-
portantly, SETD2 mutations are associated with a broad 
spectrum of leukemia other than the MLL-rearranged leu-
kemia subtype, which makes our finding more relevant in 
the clinical setting. SETD2 mutations are accompanied by 
multiple major chromosomal translocations including 
MLL-AF9, MLL-PTD and AML1-ETO, in addition to 
MLL-NRIP3 that was identified from the twin patient in this 
study. 
By taking advantage of multiple cancer patient cohorts in 
public databases, we performed comprehensive and power-
ful genomic analyses, which uncovered a mutation spectrum 
of SETD2 in human leukemia that is distinct from what has 
been observed in solid tumors. These analyses identified 
point mutation, rather than large deletion or epigenetic si-
lencing, as a major mechanism in disrupting the function of 
SETD2 in acute leukemia. 
To directly test the functional role of SETD2 disruption 
in leukemia development, we performed a series of in vitro 
and in vivo experiments. In conjunction with a major chro-
mosomal abnormality, SETD2 disruption greatly increased 
the self-renewal potential and the number of leukemia stem 
cells (LSCs). LSCs are the “seed” cells that replicate them-
selves to promote and sustain leukemic cell growth. By 
examination of the expression profile of more than 20000 
genes, the study was able to pinpoint the molecular path-
ways that may contribute to stemness of LSCs in SETD2 
mutated leukemia. Moreover, specific inhibition of the 
mTOR pathway significantly decreased the self-renewal 
potential of LSCs. 
The series of experimentation in conjunction with exten-
sive bioinformatic analyses provide novel insights into both 
cellular and molecular mechanisms upon the disruption of 
SETD2 in the heterogeneous leukemia cell population and 
the complex signaling landscape. In addition, functional 
disruption of SETD2 appears to be involved in both initia-
tion and progression stages of leukemia development, 
thereby further justifying SETD2 mutation as a critical driv-
er mutation through the course of leukemia development. 
In this new report, whole-genome and targeted sequenc-
ing in a Chinese leukemia patient cohort revealed recurrent 
loss-of-function SETD2 mutations. Importantly, extensive 
functional and genomic analyses demonstrated that disrup-
tion of SETD2 cooperates with multiple major chromoso-
mal abnormalities to promote leukemogenesis via enhanc-
ing the self-renewal potential of LSCs and activating multi-
ple signaling pathways (Figure 1). As the cancer genome 
field is shifting its trend from massive sequencing and cata-
loguing of genomic changes in patients to studies on clinical 
significance and functional importance of identified muta-
tions, this study represents an important step toward that 
direction.  
 
Figure 1  Histone modification aberration caused by SETD2 inactivation 
cooperating with chromosomal abnormalities promotes initiation and pro-
gression of leukemia. 
Moreover, the distinct epigenetic mechanism shown by dis-
ruption of SETD2 in driving human leukemia offers a new 
opportunity for the development of cancer diagnostics and 
therapeutics [4]. 
A new study from Armstrong group further strongly 
suggested a role of SETD2 in chemotherapy resistance [5]. 
Consistent with the data obtained from the Chinese cohort, 
the frequencies of SETD2 mutations in two different B-ALL 
populations were 5% and 12%, respectively. A higher prev-
alence of SETD2 mutations was observed in patients with 
MLL-rearranged (22%) and ETV6-RUNX1 (13%) de novo 
leukemias. To test the hypothesis that mutations in epige-
netic regulators may play an important role in relapse, the 
authors carried out targeted sequencing on 472 epigenetic 
regulators and frequently mutated genes including SETD2. 
At diagnosis, 22% of patients had mutations in epigenetic 
regulators. Strikingly, epigenetic mutations were signifi-
cantly enriched in the matched relapse samples (57%, 
P=0.0039). Eleven out of 30 patients gained somatic vari-
ants in the epigenetic regulators at the time of relapse. In 
sharp comparison, the mutation spectra in signaling genes 
such as KRAS, NRAS and FLT3 were similar between the 
patients at diagnosis and relapse. This well-designed clinical 
investigation indicates the potential functional involvement 
of SETD2 mutations in relapsed ALL patients that are often 
chemoresistant with a poor long-term survival.  
Simon et al. had shown that global loss of H3K36me3 is 
associated with altered chromatin accessibility, and aberrant 
RNA processing and splicing in kidney cancer. Despite the 
functional and clinical significance of SETD2 in human 
leukemia, the underlying molecular mechanisms remain 
unclear as to how loss-of-function of SETD2 contributes to 
accelerated leukemia development and chemoresistance, 
and how global reduction of an active histone mark leads to 
activation of observed cancer stem cell signatures and on-
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cogenic signaling pathways [3]. Interestingly, a high preva-
lence of SETD2 mutation (22%) in MLL associated leuke-
mia was reported in two independent cohorts [3,5]. Several 
major MLL fusion genes such as MLL-AF9, MLL-AF4 and 
MLL-ENL are known to induce aberrant H3K79 methyla-
tion via recruitment of histone modifying enzyme DOT1L. 
An intrinsic link may exist between the SETD2-H3K36 and 
the MLL fusion-H3K79 pathways. Exploring this potential 
link will not only provide new biological insights into the 
pathogenesis of MLL leukemia, but also offer novel thera-
peutic strategies in dealing with this deadly disease. Finally, 
the association of SETD2 mutations with multiple major 
chromosomal translocations implies a common mechanism 
in various subtypes of leukemia with SETD2 mutations. 
Identification of such molecular commonality may provide 
an important basis for the development of novel therapeutic 
agents for a broader spectrum of human acute leukemias. 
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